GRFS — Grifols, S.A. stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - General·ES

Latest market price

7.86

-0.01-0.13%

Overview Short InterestFilings

GRFSQT32Grifols, S.A.·NASDAQ

Overview Short InterestFilings

7.86-0.13%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OGN+0.07%$13.56 BIIB-0.56%$201.82 ZTS-0.25%$77.10 SNY-0.30%$42.95 GSK-0.35%$51.51 BMY+0.24%$65.47 PFE+0.14%$25.05 GILD+0.72%$131.15

Snapshot

Index	-	P/E	22.65	EPS (ttm)	0.35	Insider Own	-	Shs Outstand	845.97M	Perf Week	3.83%

Market Cap	7.82B	Forward P/E	6.38	EPS next Y	1.23	Insider Trans	-	Shs Float	834.63M	Perf Month	11.16%

Enterprise Value	17.05B	PEG	9.74	EPS next Q	-	Inst Own	-	Short Float	0.76%	Perf Quarter	-4.49%

Income	519.23M	P/S	0.91	EPS this Y	35.73%	Inst Trans	-	Short Ratio	9.24	Perf Half Y	-15.29%

Sales	8.56B	P/B	1.23	EPS next Y	27.91%	ROA	2.25%	Short Interest	6.34M	Perf YTD	-15.83%

Book/sh	-	P/C	6.22	EPS next 5Y	20.79%	ROE	8.43%	52W High	10.87 -27.67%	Perf Year	-27.47%

Cash/sh	-	P/FCF	8.85	EPS past 3/5Y	25.41% -5.03%	ROIC	5.47%	52W Low	6.95 13.07%	Perf 3Y	-22.77%

Dividend Est.	0.11 (1.35%)	EV/EBITDA	9.12	Sales past 3/5Y	8.53% 6.01%	Gross Margin	37.23%	Volatility	3.05% 2.38%	Perf 5Y	-48.22%

Dividend TTM	0.28 (3.58%)	EV/Sales	1.99	EPS Y/Y TTM	185.33%	Oper. Margin	16.66%	ATR (14)	0.24	Perf 10Y	-53.46%

Dividend Ex-Date	Jul 02, 2026	Quick Ratio	0.81	Sales Y/Y TTM	10.64%	Profit Margin	6.09%	RSI (14)	56.76	Recom	2.75

Dividend Gr. 3/5Y	- 4.19%	Current Ratio	2.37	EPS Q/Q	73.10%	SMA20	4.51%	Beta	0.67	Target Price	-

Payout	28.31%	Debt/Eq	1.54	Sales Q/Q	7.72%	SMA50	4.34%	Rel Volume	0.69	Prev Close	7.87

Employees	23,833	LT Debt/Eq	1.10	Earnings	Nov 10	SMA200	-6.72%	Avg Volume	701.26K	Price	7.86

IPO Date	Jun 02, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.54% -3.10%	Net Debt/EBITDA	4.94	Volume	484,873	Change	-0.13%

Analyst Ratings

Date	Action	Analyst	Rating
Mar-12-24	Downgrade	Deutsche Bank	Hold → Sell
Nov-05-21	Downgrade	Deutsche Bank	Buy → Hold
Mar-23-21	Upgrade	Credit Suisse	Neutral → Outperform
Mar-11-21	Upgrade	HSBC	Hold → Buy
Oct-28-19	Upgrade	Santander	Hold → Buy
Jun-27-19	Upgrade	JP Morgan	Neutral → Overweight
Feb-08-19	Downgrade	Berenberg	Buy → Hold
Feb-09-16	Upgrade	Berenberg	Hold → Buy
Jan-04-16	Downgrade	Morgan Stanley	Equal Weight → Underweight
Dec-02-15	Downgrade	HSBC	Buy → Hold

Latest News

Jul-28-26

Jul-28-2606:23PM

Grifols, S.A. (GIKLY) Q2 2026 Earnings Call TranscriptSeekingAlpha

02:04PM

Grifols Q2 Earnings Call Highlightsmarketbeat.com

Jul-16-26

Jul-16-2603:24PM

Oakmark International Small Cap Fund Q2 2026 Portfolio ActivitySeekingAlpha

08:00AM

Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulinsglobenewswire.com

Jul-03-26

Jul-03-2610:49AM

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)SeekingAlpha

Company

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	8,668	8,153	7,803	7,130	6,377	5,834	6,090	5,711	5,295
Cost of Goods Sold Incl. D&A	5,440	5,243	4,780	4,444	4,049	3,513	3,518	3,088	2,876
Gross Profit	3,227	2,911	3,023	2,686	2,328	2,321	2,572	2,622	2,419
Selling, General and Administrative Excl. Other	1,308	1,152	1,238	1,369	1,165	1,255	1,124	1,056	962
Research and Development	478	404	415	428	380	420	336	309	284
Other Operating Expense	-3	15	81	43	-40	-58	-24	-10	0
Operating Income	1,443	1,339	1,290	846	823	704	1,136	1,267	1,173
Interest Expense	625	677	836	558	467	277	325	363	324
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-38	4	27	-64	0	-13	191	11	7
Net Income Before Taxes	780	666	480	224	355	414	1,002	915	857
Income Taxes	150	125	250	47	95	101	193	189	155
Consolidated Net Income	527	436	170	46	195	223	705	700	704
Net Income From Continuing Operations	631	542	230	177	261	314	809	727	701
Net Income	527	436	170	46	195	223	705	700	704
EPS (Recurring)	0.78	0.64	0.25	0.10	0.33	0.32	0.83	1.06	1.03
EPS (Basic, Before Extraordinaries)	0.78	0.64	0.25	0.10	0.33	0.32	0.83	1.06	1.03
EPS (Diluted)	0.78	0.64	0.25	0.10	0.33	0.32	0.83	1.05	1.03
EBITDA	2,039	1,831	1,606	1,265	1,255	1,116	1,623	1,617	1,486
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	10.08	14.54	29.90	118.75	26.07	35.17	22.15	22.12	17.88
Price To Sales Ratio	0.62	0.78	0.65	1.10	0.91	1.31	2.08	2.69	2.38
Gross Margin	37.23	35.70	38.74	37.67	36.51	39.78	42.23	45.91	45.68
Operating Margin	16.65	16.42	16.53	11.87	12.91	12.07	18.65	22.19	22.15
Net Margin	6.08	5.35	2.18	0.65	3.06	3.82	11.58	12.26	13.30
Shares Outstanding	681	681	680	680	680	682	686	660	685
Market Capitalization	5,353	6,367	5,059	7,861	5,780	7,659	12,650	15,371	12,577
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.